Disease · MONDO_0011429
Comparisons in its trials23
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 23
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Celecoxib vs nsNSAIDs: serious adverse events | 2 of 68 | 9 of 225 | 293 | NCT00688545 | Trial comparisons |
| SC Abatacept Ages 6 to 17 vs SC Abatacept Ages 2 to 5: deaths from any cause | 0 of 173 | 0 of 46 | 219 | NCT01844518 | Trial comparisons |
| SC Abatacept Ages 6 to 17 vs SC Abatacept Ages 2 to 5: serious adverse events | 18 of 173 | 6 of 46 | 219 | NCT01844518 | Trial comparisons |
| SC Abatacept Ages 6 to 17 vs SC Abatacept Ages 2 to 5: Number of Participants With Positive Immunogenicity Response in the Cumulative Period | 8 of 172 | 7 of 46 | 218 | NCT01844518 | Trial comparisons |
| Celecoxib vs Naproxen: serious adverse events | 0 of 100 | 1 of 98 | 198 | NCT00807846 | Trial comparisons |
| Celecoxib vs Naproxen: Number of Participants With >= 30% Improvement in the Parent's Global Assessment of Overall Well-being at Week 6/Final Visit. | 47 of 98 | 54 of 98 | 196 | NCT00807846 | Trial comparisons |
| Reduced CZP Dose vs Original CZP Dose: Number of Participants With Anti-Certolizumab Pegol (Anti-CZP) Antibody Level at Week 16 | 69 of 84 | 77 of 97 | 181 | NCT01550003 | Trial comparisons |
| Adalimumab + MTX vs Adalimumab: Number of Subjects Meeting Pediatric American College of Rheumatology 30% (PedACR30) Response Criteria at the End of the Open-Label Lead-In Phase | 80 of 85 | 64 of 86 | 171 | NCT00048542 | Trial comparisons |
| Celecoxib vs Naproxen: Number of Participants With >= 30% Improvement in the Participant's Global Assessment of Overall Well-being at Week 6/Final Visit. | 33 of 75 | 45 of 83 | 158 | NCT00807846 | Trial comparisons |
| Reduced CZP Dose vs Original CZP Dose: Number of Participants With Anti-Certolizumab Pegol (Anti-CZP) Antibody Level at Week 48 | 58 of 72 | 47 of 60 | 132 | NCT01550003 | Trial comparisons |
Abatacept (Period B) vs Placebo (Period B): Number of Participants With a Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease With a Flare During Double-Blind Phase (Period B) | 12 of 60 | 33 of 62 | 122 | NCT00095173 | Trial comparisons |
| Methotrexate Arm vs Methotrexate-Prednisolone-Etanercept Arm: Clinical Remission on Medication | 3 of 43 | 9 of 42 | 85 | NCT00443430 | Trial comparisons |
| Methotrexate Arm vs Methotrexate-Prednisolone-Etanercept Arm: Proportion of Participants Who Attain Inactive Disease by 6 Months | 10 of 43 | 17 of 42 | 85 | NCT00443430 | Trial comparisons |
| Methotrexate Arm vs Methotrexate-Prednisolone-Etanercept Arm: serious adverse events | 1 of 43 | 2 of 42 | 85 | NCT00443430 | Trial comparisons |
| Double-Blind Adalimumab + MTX vs Double-Blind Placebo + MTX: Number of Subjects in the MTX Stratum With Disease Flare During the Double-Blind Phase | 14 of 38 | 24 of 37 | 75 | NCT00048542 | Trial comparisons |
| Double-Blind Adalimumab vs Double-Blind Placebo: Number of Subjects in the Non-MTX Stratum With Disease Flare During the Double-Blind Phase | 13 of 30 | 20 of 28 | 58 | NCT00048542 | Trial comparisons |
| Somatropin (With Previous Somatropin Exposure) vs Somatropin (Without Previous Somatropin Exposure): serious adverse events | 6 of 11 | 2 of 10 | 21 | NCT00174291 | Trial comparisons |
| Part 2: Etanercept vs Part 2: Placebo: Number of Participants in Part 2 With Disease Flare | 0 of 4 | 1 of 5 | 9 | NCT00078806 | Trial comparisons |
Cohort D, Arm D2P: Moderna mRNA-1273 + Withhold IS (MMF/MPA) vs Cohort E, Arm E2P: Moderna mRNA-1273 + Withhold IS (MTX): Percent of Stage 2 Pediatric Participants Who Experience Any Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection | 0 of 1 | 0 of 1 | 2 | NCT05000216 | Trial comparisons |
Cohort D, Arm D2P: Moderna mRNA-1273 + Withhold IS (MMF/MPA) vs Cohort E, Arm E2P: Moderna mRNA-1273 + Withhold IS (MTX): Percent of Stage 2 Pediatric Participants Who Experience Any Grade 1 or Higher Adverse Events Related to Study Vaccine | 0 of 1 | 0 of 1 | 2 | NCT05000216 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0011429/comparisons